

## **Positions** <sup>[1]</sup>

In order to find long-term, sustainable solutions to global health challenges, we need to engage in constructive discussions and be transparent about our views. We engage in policy debates and share the company's perspective on issues including access to healthcare, ethics, R&D and quality of medicines, striving for open and constructive interaction.

As part of our ongoing commitment to transparency, we state our position on key issues affecting our business and of specific interest to our stakeholders.

## **Access**

[Access to healthcare \(PDF 0.3 MB\)](#) <sup>[2]</sup>

[Value-Based Healthcare \(PDF 0.1 MB\)](#) <sup>[3]</sup>

## **R&D**

[Animal research \(PDF 0.1 MB\)](#) <sup>[4]</sup>

[Clinical study transparency \(PDF 0.1 MB\)](#) <sup>[5]</sup>

[Medicines for Patients with Rare Diseases \(PDF 0.1 MB\)](#) <sup>[6]</sup>

[Nanotechnology-based medicine \(PDF 0.2 MB\)](#) <sup>[7]</sup>

[Post-trial Access \(PDF 0.1 MB\)](#) <sup>[8]</sup>

[Pre-Approval Access to Novartis Products through MAPs \(PDF 0.3 MB\)](#) <sup>[9]</sup>

[Responsible Clinical Trials \(PDF 0.1 MB\)](#) <sup>[10]</sup>

## **Quality and safety of medicines**

[Falsified and Counterfeit Medical Products \(PDF 0.1 MB\)](#) <sup>[11]</sup>

## **Intellectual property**

[Intellectual Property \(PDF 0.2 MB\)](#) [12]

[Competitive off-patent markets \(PDF 0.2 MB\)](#) [13]

[Safe harbor exemption \(Bolar provision\) \(PDF 0.2 MB\)](#) [14]

[Regulatory data protection \(PDF 0.2 MB\)](#) [15]

## Ethics

[Genetic testing of employees \(PDF 0.1 MB\)](#) [16]

[Ethical principles for transplantation studies \(PDF 0.2 MB\)](#) [17]

[Novartis Position on Collaborating with Patient Organizations \(PDF 0.2 MB\)](#) [18]

[Responsible Business Initiative - Novartis Attitude and Context \(PDF 0.2 MB\)](#) [19]

## Biologics

[Biosimilars: key regulatory and market access aspects \(PDF 0.1 MB\)](#) [20]

## Environment

[Biodiversity / Bioprospecting \(PDF 0.2 MB\)](#) [21]

[Pharmaceuticals in the environment \(PDF 0.2 MB\)](#) [22]

## Taxation

[Novartis Tax Policy Statement \(PDF 0.1 MB\)](#) [23]

---

**Source URL:** <https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/positions>

### Links

[1] <https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/positions>

[2] <https://www.novartis.com/sites/www.novartis.com/files/access-to-healthcare-perspective.pdf>

[3] <https://www.novartis.com/sites/www.novartis.com/files/novartis-position-on-value-based-healthcare.pdf>

[4] <https://www.novartis.com/sites/www.novartis.com/files/animal-research.pdf>

[5] <https://www.novartis.com/sites/www.novartis.com/files/clinical-trial-data-transparency.pdf>

[6] <https://www.novartis.com/sites/www.novartis.com/files/medicines-for-patients-with-rare-diseases.pdf>

[7] <https://www.novartis.com/sites/www.novartis.com/files/nanotechnology-based-medicine.pdf>

[8] <https://www.novartis.com/sites/www.novartis.com/files/novartis-position-on-post-trial-access.pdf>

[9] <https://www.novartis.com/sites/www.novartis.com/files/novartis-position-pre-approval-access.pdf>

[10] <https://www.novartis.com/sites/www.novartis.com/files/novartis-position-on-responsible-clinical-trials.pdf>

[11] <https://www.novartis.com/sites/www.novartis.com/files/falsified-counterfeit-medical-products-07-2017.pdf>

[12] <https://www.novartis.com/sites/www.novartis.com/files/novartis-intellectual-property-position.pdf>

- [13] <https://www.novartis.com/sites/www.novartis.com/files/competitive-off-patent-markets.pdf>
- [14] <https://www.novartis.com/sites/www.novartis.com/files/safe-harbor-exemption.pdf>
- [15] <https://www.novartis.com/sites/www.novartis.com/files/regulatory-data-protection.pdf>
- [16] <https://www.novartis.com/sites/www.novartis.com/files/genetic-testing.pdf>
- [17] <https://www.novartis.com/sites/www.novartis.com/files/ethical-principles-for-transplantation-studies.pdf>
- [18] <https://www.novartis.com/sites/www.novartis.com/files/novartis-position-on-collaborating-with-patient-organizations.pdf>
- [19] <https://www.novartis.com/sites/www.novartis.com/files/responsible-business-initiative-novartis-attitude-context.pdf>
- [20] <https://www.novartis.com/sites/www.novartis.com/files/biosimilars-key-regulatory-and-market-access-aspects.pdf>
- [21] <https://www.novartis.com/sites/www.novartis.com/files/biodiversity.pdf>
- [22] <https://www.novartis.com/sites/www.novartis.com/files/pharmaceuticals-environment.pdf>
- [23] <https://www.novartis.com/sites/www.novartis.com/files/tax-policy-statement.pdf>